for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Neurocrine Biosciences, Inc.

NBIX.OQ

Latest Trade

100.83USD

Change

-0.67(-0.66%)

Volume

336,178

Today's Range

100.49

 - 

102.47

52 Week Range

64.73

 - 

125.46

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
101.50
Open
102.08
Volume
336,178
3M AVG Volume
14.07
Today's High
102.47
Today's Low
100.49
52 Week High
125.46
52 Week Low
64.73
Shares Out (MIL)
91.58
Market Cap (MIL)
9,260.51
Forward P/E
116.15
Dividend (Yield %)
--

Next Event

Q3 2019 Neurocrine Biosciences Inc Earnings Release

Latest Developments

More

AbbVie Submits New Drug Application To U.S. FDA For Investigational Elagolix For Management Of Heavy Menstrual Bleeding Associated With Uterine Fibroids In Women

Neurocrine Biosciences Posts Q2 EPS Of $0.54

Neurocrine Biosciences Says FDA accepts NDA For Opicapone As An Adjunctive Treatment For Patients With Parkinson's Disease

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson's disease. Its product pipeline also includes NBI-640756, which targets tremor and NBI-74788, which targets classic congenital adrenal hyperplasia. Its R&D focus is on addressing diseases and disorders of the central nervous and endocrine systems.

Industry

Biotechnology & Drugs

Contact Info

12780 El Camino Real

+1.858.6177600

http://www.neurocrine.com/

Executive Leadership

William H. Rastetter

Independent Chairman of the Board

Kevin C. Gorman

Chief Executive Officer, Director

Matthew C. Abernethy

Chief Financial Officer

Eric S. Benevich

Chief Commercial Officer

Haig P. Bozigian

Chief Development Officer

Key Stats

1.84 mean rating - 19 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.2K

2018

0.5K

2019(E)

0.8K
EPS (USD)

2016

-1.630

2017

-1.620

2018

0.220

2019(E)

0.871
Price To Earnings (TTM)
757.51
Price To Sales (TTM)
15.30
Price To Book (MRQ)
19.14
Price To Cash Flow (TTM)
389.56
Total Debt To Equity (MRQ)
82.38
LT Debt To Equity (MRQ)
82.38
Return on Investment (TTM)
2.07
Return on Equity (TTM)
1.89

Latest News

BRIEF-Neurocrine Biosciences Q1 Loss Per Share $0.47

* NEUROCRINE BIOSCIENCES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

FDA needs more time to review AbbVie, Neurocrine's uterine pain drug

AbbVie Inc and Neurocrine Biosciences Inc said on Tuesday the U.S. Food and Drug Administration notified the companies that it requires more time to review the marketing application for their uterine pain drug.

FDA needs more time to review AbbVie, Neurocrine's uterine pain drug

AbbVie Inc and Neurocrine Biosciences Inc said on Tuesday the U.S. Food and Drug Administration notified the companies that it requires more time to review the marketing application for their uterine pain drug.

CORRECTED-FDA extends review for AbbVie, Neurocrine's uterine pain drug

AbbVie Inc and Neurocrine Biosciences Inc said on Tuesday the U.S. Food and Drug Administration notified the companies that it requires more time to review the marketing application for their uterine pain drug.

BRIEF-Abbvie And Neurocrine Biosciences Announce PDUFA Target Date Of Q3 2018 For Elagolix In Endometriosis Associated Pain

Abbvie And Neurocrine Biosciences Announce Pdufa Target Date Of Q3 2018 For Elagolix In Endometriosis :

BRIEF-Neurocrine Will File NDA For Opicapone For Parkinson's Disease Based On Existing Pivotal Clinical Trial Data

* NEUROCRINE BIOSCIENCES WILL FILE NEW DRUG APPLICATION FOR OPICAPONE FOR PARKINSON'S DISEASE BASED ON EXISTING PIVOTAL CLINICAL TRIAL DATA

BRIEF-Neurocrine Biosciences Reports Q4 Earnings Per Share $0.07

* NEUROCRINE BIOSCIENCES REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS AND PROVIDES INVESTOR UPDATE FOR 2018

BRIEF-Neurocrine Biosciences Presents Long-Term Data Analyses From Open-Label Kinect 4 Phase III Study

* NEUROCRINE BIOSCIENCES PRESENTS LONG-TERM DATA ANALYSES FROM OPEN-LABEL KINECT 4 PHASE III STUDY DEMONSTRATING INGREZZA® IMPROVES TARDIVE DYSKINESIA SYMPTOMS Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-Neurocrine Biosciences appoints Matt Abernethy as CFO

* Neurocrine Biosciences appoints Matt Abernethy as chief financial officer

BRIEF-Neurocrine Biosciences reports Q3 loss per share $0.13

* Q3 earnings per share view $-0.49 -- Thomson Reuters I/B/E/S

BRIEF-Neurocrine initiates Phase IIb clinical study of Ingrezza

* Neurocrine initiates phase IIb clinical study of once-daily Ingrezza in children and adolescents with Tourette syndrome

BRIEF-Neurocrine granted FDA orphan drug designation for Valbenazine

* Neurocrine granted FDA orphan drug designation for valbenazine for the treatment of pediatric patients with Tourette syndrome Source text for Eikon: Further company coverage:

BRIEF-Neurocrine announces FDA approval of 80 mg Ingrezza

* Neurocrine announces FDA approval of 80 mg Ingrezza® (valbenazine) capsules for the treatment of adults with tardive dyskinesia (TD)

BRIEF-Perceptive Advisors reports 5.3 pct passive stake in Neurocrine Biosciences

* Perceptive Advisors LLC reports 5.3 percent passive stake in Neurocrine Biosciences Inc as of September 6, 2017 - SEC filing Source: (http://bit.ly/2wOUVQY) Further company coverage:

BRIEF-Neurocrine Biosciences Q2 loss per share $0.68

* Q2 earnings per share view $-0.66 -- Thomson Reuters I/B/E/S

BRIEF-Neurocrine Biosciences says PDUFA goal date is Oct. 14 for Ingrezza 80 mg capsules

* Neurocrine Biosciences Inc - has been advised that PDUFA goal date is october 14, 2017 for Ingrezza 80 mg capsules - sec filing Source text for Eikon: (http://bit.ly/2spiVra) Further company coverage:

BRIEF-Neurocrine Bio's Ingrezza fails study in pedriatric Tourette's patients

* Neurocrine announces phase ii results of vmat2 inhibitor ingrezza® for treatment of tourette syndrome

BRIEF-Neurocrine Biosciences reports Q1 loss per share $0.90

* Q1 earnings per share view $-0.74 -- Thomson Reuters I/B/E/S

BRIEF-Neurocrine Biosciences prices $450 mln convertible senior notes offering

* Priced offering of $450.0 million aggregate principal amount of 2.25% convertible senior notes due 2024 Source text for Eikon: Further company coverage:

Neurocrine Biosciences gets FDA's OK for movement disorder drug

The U.S. Food and Drug Administration approved Neurocrine Biosciences Inc's drug to treat tardive dyskinesia, a side effect of antipsychotic medications characterized by uncontrolled movements of the face and body, the company said.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up